In consultation: Guidance and quality standards
Showing 1 to 1 of 1
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |